

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>4</sup> :</b> <b>C12N 7/100, G01N 33/53, 33/554</b> <b>G01N 33/569</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/02173</b> <b>(43) International Publication Date:</b> <b>8 March 1990 (08.03.90)</b>
<b>(21) International Application Number:</b> PCT/US89/03580 <b>(22) International Filing Date:</b> 18 August 1989 (18.08.89)  <b>(30) Priority data:</b> 239,106 31 August 1988 (31.08.88) US  <b>(71) Applicant:</b> RESEARCH DEVELOPMENT CORPORATION [US/US]; 402 North Divison Street, Carson City, NV 89703 (US).  <b>(72) Inventors:</b> EVINGER-HODGES, Mary, Jean ; 1030 Margate, Pearland, TX 77584 (US). BRESSER, Joel ; 2830 South Bartell, Building 3, Apartment 34, Houston, TX 77054 (US).  <b>(74) Agent:</b> GOODMAN, Rosanne; Fulbright & Jaworski, 1301 McKinney Street, Houston, TX 77010 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ONE-STEP IN SITU HYBRIDIZATION ASSAY  <b>(57) Abstract</b>  A quantitative, sensitive, one-step <i>in situ</i> hybridization assay is provided which detect as few as 1-5 copies of target biopolymer per cell and may be accomplished in 5 minutes to 5 hours. There is provided a simultaneous assay for detecting multiple biopolymers within the same cell.		

CGK00010422

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

ONE-STEP IN SITU HYBRIDIZATION ASSAY

## BACKGROUND OF THE INVENTION

1. Field of the invention.

The present invention relates to the field of in situ hybridization assays useful for detecting as few as 1-5 copies of target nucleic acid per cell. This assay method significantly increases the sensitivity of detection of nucleic acids over other known methods. In addition, this hybridization method is accomplished with far greater speed than has been reported for other in situ assays. This present invention also provides a method for the rapid and sensitive detection of nucleic acids and proteins in the same cell. A kit is provided for a simple one step fixation/hybridization in situ assay.

2. Description of the prior art.

In situ hybridization provides a technique for the determination and quantitation of biopolymers such as nucleic acids (DNA and RNA) and proteins in tissues at the single cell level. Such hybridization techniques can detect the presence or absence of specific genes in tissues at the single cell level. In situ hybridization

1 procedures may also be utilized to detect the expression  
of gene products at the single cell level.

By the use of specific nucleic acid (RNA or DNA)  
probes, genetic markers for infection and other disease  
5 states may be detected. Certain genetic diseases are  
characterized by the presence of genes which are not  
present in normal tissue. Other diseased conditions are  
characterized by the expression of RNAs or RNA translation  
products (i.e. peptides or proteins) which are not  
10 expressed in normal cells. Some disease states are  
characterized by the absence of certain genes or gene  
portions, or the absence or alteration of expression of  
gene products or proteins. Antibody probes specific for  
target antigenic biopolymers have also been used to  
15 identify the presence of viral proteins or gene products.

Current methods allow the detection of these  
markers but are relatively time consuming and of limited  
sensitivity. Hybridization techniques are based on the  
ability of single stranded DNA or RNA to pair (or  
20 hybridize) with a complementary nucleic acid strand. This  
hybridization reaction allows the development of specific  
probes that can identify the presence of specific genes  
(DNA), or polynucleotide sequences or the transcription  
and expression of those genes (mRNA).

25 Solution hybridization methods which require the  
destruction of the cell and the isolation of the nucleic  
acids from the cell prior to carrying out the  
hybridization reaction sacrifice the cellular integrity,  
spatial resolution and sensitivity of detection. In situ  
30 hybridization allows the detection of RNA or DNA sequences  
within individual cells. In situ hybridization yields  
greater sensitivity than solution hybridization by means  
of eliminating the dilution of a particular target gene,  
nucleic acid, or protein by the surrounding and extraneous  
35 RNA and DNA of other cells. In situ hybridization also

1 allows for the simultaneous detection of multiple  
substances, i.e. genes, nucleic acids or proteins within  
individual cells, permitting the identification of a  
particular cell expressing a cellular gene or viral  
5 sequence. In addition, since in situ hybridization  
analysis is performed and quantitated for single cells,  
minimal sample and reagents are required.

Prior to the present invention, in situ  
hybridization procedures were only capable of detecting  
10 nucleic acids present at greater than ten copies per  
cell. Such procedures required multiple steps and at  
least 4 hrs. to over 14 days to perform.

#### 15 SUMMARY OF THE INVENTION

It is an object of the present invention to  
provide a fast, sensitive in situ hybridization procedure  
capable of detecting polynucleotides when present at a  
concentration as low as 1-5 copies per cell.

20 It is a further object of the present invention  
to provide a fast and sensitive in situ hybridization  
procedure capable of detecting more than one target  
molecule in an individual cell.

It is a further object of the present invention  
25 to provide an in situ hybridization procedure that could  
be carried out within about 5 minutes to four hours.

It is a further object of the present invention  
to provide an in situ hybridization procedure that could  
be quantitative for as few as 1-5 molecules of target  
30 nucleic acid per cell.

It is a further object of the present invention  
to provide an in situ hybridization procedure that could  
simultaneously detect multiple biopolymers.

It is a further object of the present invention  
35 to provide an in situ hybridization procedure that could

1 be carried out in one step.

It is a further object of the present invention to provide an in situ hybridization procedure that could be carried out on cells in suspension.

5 It is a further object of the present invention to provide an in situ hybridization procedure that could eliminate the need for immobilization of cells or tissues onto a solid support before analysis.

10 It is a further object of the present invention to provide an in situ hybridization procedure which could deliver a probe to living cells, maintain the viability of the cells and record the occurrence of hybridization by chemical or physical means or by an effect on one or more biological properties of the cell or its components.

15 It is a further object of the present invention to be able to simultaneously detect and discriminate between the DNA, RNA and protein for the same gene in the same cell using the process of in situ hybridization.

20 It is a further object of the present invention to provide an assay kit for one step in situ hybridization.

The present invention provides a method for the detection of biopolymers within individual cells or tissue sections either in solution or after being deposited on a solid support. Optimization of each component of the  
25 procedure as provided by the present invention allows a rapid, sensitive hybridization assay which may be accomplished in one step. Target biopolymer molecules may be quantitated at a level of as few as 1-5 molecules per cell. This hybridization assay may be used to detect  
30 levels of polynucleotides in cells such as bone marrow and peripheral blood, in tumors, in tissue sections or in tissue cultured cells. The hybridization procedure of the present invention can detect polynucleotides in single cells with the sensitivity as few as 1-5 molecules per  
35 cell in as little as 5 minutes to 4 hours. This procedure

1       also allows simultaneous detection of more than one  
different polynucleotide sequence in an individual cell.  
The present invention also allows detection of proteins  
and polynucleotides in the same cell.

5               Briefly, cells, either as single cell suspensions  
or as tissue slices may be deposited on solid supports  
such as glass slides. Alternatively, cells are placed  
into a single cell suspension of about  $10^5$ - $10^6$  cells  
per ml. The cells are fixed by choosing a fixative which  
10       provides the best spatial resolution of the cells and the  
optimal hybridization efficiency.

15              The hybridization is then carried out in the same  
solution which effects fixation. This solution contains  
both a fixative and a chaotropic agent such as formamide.  
Also included in this solution is a hybrid stabilizing  
agent such as concentrated lithium chloride or ammonium  
acetate solution, a buffer, low molecular weight DNA  
and/or ribosomal RNA (sized to 50 bases) to diminish  
non-specific binding, and a pore forming agent to  
20       facilitate probe entry into the cells. Nuclease  
inhibitors such as vanadyl ribonucleoside complexes may  
also be included.

25              To the hybridization solution is added a probe,  
to hybridize with a target polynucleotide. The most  
preferable probe is a single-stranded anti-sense probe.  
For hybridization to cellular RNA, a probe of  
approximately 75 to 150 bases in length is used. For  
hybridization to cellular DNA, a probe of approximately  
15-50 bases is used. An antibody probe may be utilized to  
30       bind to a target protein or antigen. The hybridization  
solution containing the probe is added in an amount  
sufficient to cover the cells when using immobilized  
cells. When utilizing cells in suspension, a 3X  
concentrate of hybridization cocktail is added to the  
35       cells. Alternatively, the cells may be resuspended in the

1        hybrid solution. The cells are then incubated at the  
prescribed temperature for at least 5 minutes. The probe  
is utilized at a high concentration of at least about  
1 ug/ml of hybrid mix in order to give optimal results in  
5        this time frame.

      The probes may be detectably labeled prior to the  
hybridization reaction. Alternatively, a detectable label  
may be selected which binds to the hybridization product.  
Probes may be labeled with any detectable group for use in  
10       practicing the invention. Such detectable group can be  
any material having a detectable physical or chemical  
property. Such detectable labels have been well-developed  
in the field of immunoassays and in general most any label  
useful in such methods can be applied to the present  
15       invention. Particularly useful are enzymatically active  
groups, such as enzymes (see Clin. Chem., 22:1243 (1976)),  
enzyme substrates (see British Pat. Spec. 1,548,741),  
coenzymes (see U.S. Patents Nos. 4,230,797 and 4,238,565)  
and enzyme inhibitors (see U.S. Patent No. 4,134,792);  
20       fluorescers (see Clin. Chem., 25:353 (1979); chromophores;  
luminescers such as chemiluminescers and bioluminescers  
(see Clin. Chem., 25:512 (1979)); specifically bindable  
ligands; proximal interacting pairs; and radioisotopes  
such as  $^3\text{H}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$  and  $^{14}\text{C}$ .

25       The invention of the present application provides  
a means of carrying out the fixation, prehybridization,  
hybridization and detection steps normally associated with  
in situ hybridization procedures all in one step. By  
modifying the components of this "one-step" solution, a  
30       convenient temperature may be used to carry out the  
hybridization reaction. Furthermore, this application  
provides a hybridization assay which can be accomplished  
with viable or non-viable cells in solution. In either  
case, the assay is rapid, requiring as little as 1 to 5

35



1 minutes to complete, and sensitive, detecting as few as  
1-5 molecules of polynucleotide within a cell.

5 The superior results of the invention of the  
present application are postulated to occur by preventing  
precipitation of cellular constituents onto mRNA or the  
covalent modification of mRNA, the destabilization of  
ribosomal RNA subunit binding, and promotion of  
accessibility of full length mRNA for hybrid formation by  
inducing single-strandedness in cellular RNA and/or DNA.  
10 The present invention arose out of the applicant's  
discovery of the strong correlation between cellular RNA  
single-strandedness and the rapid kinetics of  
hybridization which yielded a highly sensitive assay  
procedure.

15 In one aspect, the present invention provides a  
simple method to determine the optimal fixation/  
prehybridization/hybridization/detection conditions for  
any tissue type so that: (1) single molecules may be  
detected, (2) cellular morphology will be preserved and  
20 (3) the total reaction time will be reduced to 5 minutes  
to 4 hours.

Briefly, in order to predict the optimal  
conditions to achieve this rapid and sensitive  
hybridization, a cellular specimen in multiple samples,  
25 either in suspension or deposited on glass slides, are  
exposed first to a fixative and subsequently to a  
hybridization solution.

The fixative is selected from the group  
consisting of 95% ethanol/5% acetic acid, 75% ethanol/20%  
30 acetic acid, 50% methanol/50% acetone and 10%  
formaldehyde/90% methanol (all v/v). Other useful  
fixatives will be obvious to one skilled in the art as  
long as the fixative selected allows at least a 70% shift  
of double stranded to single stranded cellular  
35 polynucleotides while maintaining cellular spatial

1 relationships. The duration of exposure to the fixative  
is from 1 to 180 min. Preferably, 1 to 30 min., and most  
preferably 20 min. The temperature of the fixation  
procedure is preferably -20°C to 50°C and most preferably  
5 20°C. A subsequent exposure to 70% ethanol/30% water for  
0.5 min. to 20 min. at -20°C to 30°C may be utilized if  
samples are to be stored prior to hybridization.

The hybridization solution consists of a  
chaotropic denaturing agent, a buffer, a pore forming  
agent, a hybrid stabilizing agent, non-specific  
10 nucleotides, and a target specific probe.

The chaotropic denaturing agent (Robinson, D. W.  
and Grant, M. E. (1966) J. Biol. Chem. 241: 4030;  
Hamaguchi, K. and Geiduscheck, E. P. (1962) J. Am. Chem.  
15 Soc. 84: 1329) is selected from the group consisting of  
formamide, urea, thiocyanate, guanidine, trichloroacetate,  
tetramethylamine, perchlorate, and sodium iodide. Any  
buffer which maintains pH at least between 7.0 and 8.0 may  
be utilized.

20 The pore forming agent is for instance, a  
detergent such as Brij 35, Brij 58, sodium dodecyl  
sulfate, CHAPS<sup>TM</sup> Triton X-100. Depending on the  
location of the target biopolymer, the pore-forming agent  
is chosen to facilitate probe entry through plasma, or  
25 nuclear membranes or cellular compartmental structures.  
For instance, 0.05% Brij 35 or 0.1% Triton X-100 will  
permit probe entry through the plasma membrane but not the  
nuclear membrane. Alternatively, sodium desoxycholate  
will allow probes to traverse the nuclear membrane. Thus,  
30 in order to restrict hybridization to the cytoplasmic  
biopolymer targets, nuclear membrane pore-forming agents  
are avoided. Such selective subcellular localization  
contributes to the specificity and sensitivity of the  
assay by eliminating probe hybridization to complimentary  
35 nuclear sequences when the target biopolymer is located in

1 the cytoplasm. Agents other than detergents such as  
fixatives may serve this function. Furthermore, a  
biopolymer probe may also be selected such that its size  
is sufficiently small to traverse the plasma membrane of a  
5 cell but is too large to pass through the nuclear membrane.

Hybrid stabilizing agents such as salts of mono-  
and di-valent cations are included in the hybridization  
solution to promote formation of hydrogen bonds between  
complimentary sequences of the probe and its target  
10 biopolymer. Preferably lithium chloride or ammonium  
acetate at a concentration from .15M to 1.5M is used; most  
preferably, the concentration of lithium chloride 0.8M.

In order to prevent non-specific binding of  
nucleic acid probes, nucleic acids unrelated to the target  
15 biopolymers are added to the hybridization solution at a  
concentration of 100 fold the concentration of the probe.

Specimens are removed after each of the above  
steps and analyzed by observation of cellular morphology  
as compared to fresh, untreated cells using a phase  
20 contrast microscope. The condition determined to maintain  
the cellular morphology and the spatial resolution of the  
various subcellular structures as close as possible to the  
fresh untreated cells is chosen as optimal for each step.

In addition, cellular nucleic acids were stained  
25 with about 50 ug/ml propidium iodide dye. This dye has a  
specific characteristic fluorescent emission (about 480  
nm, green) when the nucleic acid is single-stranded and  
emits at a different wave length (about 615 nm, red) when  
the nucleic acid is double-stranded. The dye utilized may  
30 be dependent upon whether the target sequence for the  
particular assay is RNA or DNA. If the assay is to detect  
low copy numbers of DNA, then a DNA detecting dye such as  
acridine orange, tetrahydrofuran, methyl green, pyronin Y  
and azure B is used, and the nuclear DNA is analyzed for  
35 the amount of single or double-strandedness. If instead,

1 the assay is to be used to detect low copy numbers of RNA,  
then RNA dyes such as Acridines, Azines, Xanthenes,  
Oxazines, and Thiazines are used and the cytoplasmic RNA  
is analyzed for the amount of single or  
5 double-strandedness. Regardless of whether the assay is  
used to analyze RNA or DNA, the optimal conditions are  
reached when the nucleic acid to be detected has undergone  
a 70% shift from double-strandedness to  
single-strandedness. When the shift of the secondary  
10 structure of the nucleic acid from double-strandedness to  
single-strandedness has reached at least 70%, and there is  
no decrease in the total amount of fluorescence, then the  
conditions have been adjusted according to the present  
invention and will permit optimal hybridization and  
15 detection of as few as 1-5 molecules of target nucleic  
acid within a single cell. Furthermore, the time required  
for optimal hybridization can be determined from the  
amount of time necessary for at least 70% of the cellular  
nucleic acid to become single-stranded.

20 In the most preferred embodiment, the  
hybridization assay of the present invention provides a  
method for assaying biopolymers in a cell sample having  
substantially intact membranes comprising a single step of  
incubating the cells with a fixation/hybridization  
25 solution containing a single-stranded RNA probe, and  
subsequently detecting the amount of probe hybridized to  
the target nucleic acid. The samples are then washed and  
the amount of target nucleic acids are determined by  
quantitation either photographically through a microscope  
30 with fluorescent capabilities or by direct reading of the  
fluorescence with an image analysis system such as a  
Meridan ACAS 470 work station (Meridian Instruments,  
Okemos, Michigan).

35

## BRIEF DESCRIPTION OF THE DRAWINGS

1           Figure 1 demonstrates the optimal temperatures of one-step In Situ Hybridization.

5           Figure 2 demonstrates the kinetics of the One-Step In Situ Hybridization reaction.

          Figure 3 demonstrates the changes in secondary structure of cellular RNA as a function of efficiency of the In Situ Hybridization reaction.

10          Figure 4 demonstrates the detection of oncogenes in normal peripheral blood by One-Step In Situ Hybridization.

          Figure 5 demonstrates the detection of oncogenes in solid tissue samples by One-Step In Situ Hybridization.

15          Figure 6 demonstrates the detection of HIV in a seronegative, asymptomatic, high risk individual by One-Step In Situ Hybridization.

          Figure 7 demonstrates the automated digital analysis of the fluorescence within cells after One-Step In Situ Hybridization.

20          Figure 8 demonstrates a quantitative analysis of One-Step In Situ Hybridization data.

          Figure 9 demonstrates the One-Step In Situ Hybridization reaction performed on cells in solution.

          Figure 10 demonstrates a Southern Blot.

25          Figure 11 demonstrates an RNA dot blot.

          Figure 12 demonstrates the detection by One-Step In Situ Hybridization of the Human Immune Deficiency Syndrome Virus (HIV) or Cytomegalovirus (CMV) in the peripheral blood of a patient with Kaposi Sarcoma.

30          Figure 13 demonstrates the detection by One-Step In Situ Hybridization of oncogenes in the cell line K562.

## DETAILED DESCRIPTION OF THE INVENTION

Treatment of Sample

## 1. Cells/Tissues on Solid Support

In one embodiment of this version of the One-Step in situ hybridization procedure of the present invention the specimen may be deposited onto a solid support. Specimens constitute any material which is composed of or contains cells or portions of cells. The cells may be living or dead, so long as the target biopolymer (DNA, RNA or protein) is unaltered and undamaged and capable of detection. The specimen should contain cells with substantially intact membranes. Although it is not necessary that all membranes of the cellular structure be intact, the membranes must be sufficiently preserved to allow: retention of the target biopolymer, introduction of the detecting probe to the site of the target biopolymer and preservation of antigenicity of any target membrane components.

Techniques for depositing the specimens on the solid support will depend upon the cell or tissue type and may include, for example, standard sectioning of tissue or smearing or cytocentrifugation of single cell suspensions.

Many types of solid supports may be utilized to practice the invention. Supports which may be utilized include, but are not limited to, glass, Scotch tape (3M), nylon, Gene Screen Plus (New England Nuclear) and nitrocellulose. Most preferably glass microscope slides are used. The use of these supports and the procedures for depositing specimens thereon will be obvious to those of skill in the art. The choice of support material will depend upon the procedure for visualization of cells and the quantitation procedure used. Some filter materials are not uniformly thick and, thus, shrinking and swelling during in situ hybridization procedures is not uniform.

1 In addition, some supports which autofluoresce will  
interfere with the determination of low level  
fluorescence. Glass microscope slides are most  
preferable as a solid support since they have high  
5 signal-to-noise ratios and can be treated to better retain  
tissue.

The present invention may also be utilized to  
detect biopolymers in cells in suspension.

Irregardless of whether the cell specimen is in  
10 suspension or on solid supports, the hybridization  
procedure is carried out utilizing a single hybridization  
solution which also fixes the cells. This fixation is  
accomplished in the same solution and along with the  
hybridization reaction. The fixative may be selected from  
15 the group consisting of any precipitating agent or  
cross-linking agent used alone or in combination, and may  
be aqueous or non-aqueous. The fixative may be selected  
from the group consisting of formaldehyde solutions,  
alcohols, salt solutions, mercuric chloride, sodium  
20 chloride, sodium sulfate, potassium dichromate, potassium  
phosphate, ammonium bromide, calcium chloride, sodium  
acetate, lithium chloride, cesium acetate, calcium or  
magnesium acetate, potassium nitrate, potassium  
dichromate, sodium chromate, potassium iodide, sodium  
25 iodate, sodium thiosulfate, picric acid, acetic acid,  
paraformaldehyde, sodium hydroxide, acetones, chloroform,  
glycerin, thymol, etc. Preferably, the fixative will  
comprise an agent which fixes the cellular constituents  
through a precipitating action and has the following  
30 characteristics: the effect is reversible, the cellular  
morphology is maintained, the antigenicity of desired  
cellular constituents is maintained, the nucleic acids are  
retained in the appropriate location in the cell, the  
nucleic acids are not modified in such a way that they  
35 become unable to form double or triple stranded hybrids,

1 and cellular constituents are not affected in such a way  
so as to inhibit the process of nucleic acid hybridization  
to all resident target sequences. Choice of fixatives and  
fixation procedures can affect cellular constituents and  
5 cellular morphology; such effects can be tissue specific.  
Preferably, fixatives for use in the invention are  
selected from the group consisting of ethanol,  
ethanol-acetic acid, methanol, and methanol-acetone which  
fixatives afford the highest hybridization efficiency with  
10 good preservation of cellular morphology.

Fixatives most preferable for practicing the  
present invention include 10-40% ethanol, methanol,  
acetone or combinations thereof. These fixatives provide  
good preservation of cellular morphology and preservation  
15 and accessibility of antigens, and high hybridization  
efficiency.

Simultaneously, the "fixative" component of the  
solution may contain a compound which fixes the cellular  
components by cross-linking these materials together, for  
20 example, glutaraldehyde or formaldehyde. While this  
cross-linking agent must meet all of the requirements  
above for the precipitating agent, it is generally more  
"sticky" and causes the cells and membrane components to  
be secured or sealed, thus, maintaining the  
25 characteristics described above. The cross linking agents  
when used are preferably less than 10% (v/v).

Cross-linking agents, while preserving  
ultrastructure, often reduce hybridization efficiency;  
they form networks trapping nucleic acids and antigens and  
30 rendering them inaccessible to probes and antibodies.  
Some also covalently modify nucleic acids preventing later  
hybrid formation.

Typically, 20%-30% ethanol, 5% formalin and 5%  
acetone are used as a fixative for most tissues including  
35



1 peripheral blood, bone marrow, breast, lung, cervical  
sections, cardiac and skeletal muscle, and eye.

#### Prehybridization Treatments

According to the present invention no  
5 prehybridization step is necessary. Blocking nonspecific  
binding of probe and facilitating probe entry can be  
accomplished in the fixation/hybridization solution.

#### Hybridizations

Nucleic acid hybridization is a process where two  
10 or more mirror images or opposite strands of DNA, RNA,  
oligonucleotides, polynucleotides, or any combination  
thereof recognize one another and bind together through  
the formation of some form of either spontaneous or  
induced chemical bond, usually a hydrogen bond. The  
15 degree of binding can be controlled based on the types of  
nucleic acids coming together, and the extent of "correct"  
binding as defined by normal nucleic acids coming  
together, and the extent of "correct" binding as defined  
by normal chemical rules of bonding and pairing. For  
20 example, if the binding of two strands forms 9 out of 10  
correct matches along a chain of length 10, the binding is  
said to be 90% homologous.

Cellular nucleic acid sequences are detected by  
the process of molecular hybridization. The probe must be  
25 "labeled" in some way so to allow "detection" of any  
complementary cellular nucleic acid sequences present  
within the individual cells.

In the present invention, the term  
"hybridization" also means the binding of an antibody to a  
30 target antigen.

#### Types of Probes

A probe is defined as genetic material DNA, RNA,  
or oligonucleotides or polynucleotides comprised of DNA or  
RNA and antibodies. The DNA or RNA may be composed of the  
35 bases adenosine, uridine, thymidine, guanine, cytosine, or

1 any natural or artificial chemical derivatives thereof.  
The probe is capable of binding to a complementary or  
mirror image target cellular genetic sequence through one  
or more types of chemical bonds, usually through hydrogen  
5 bond formation. The extent of binding is referred to as  
the amount of mismatch allowed in the binding or  
hybridization process; the extent of binding of the probe  
to the target cellular sequences also relates to the  
degree of complementarity to the target sequences. The  
10 size of the probe is adjusted to be of such size that it  
forms stable hybrids at the desired level of mismatch;  
typically, to detect a single base mismatch requires a  
probe of approximately 12-50 bases. Larger probes (from  
50 bases up to tens of thousands of bases) are more often  
15 used when the level of mismatch is measured in terms of  
overall percentage of similarity of the probe to the  
target cellular genetic sequence. The size of the probe  
may also be varied to allow or prevent the probe from  
entering or binding to various regions of the genetic  
20 material or of the cell. Similarly, the type of the probe  
(for example, using RNA versus DNA) may accomplish these  
objectives. The size of the probe also affects the rate  
of probe diffusion, probability of finding a cellular  
target match, etc. Typically, double-stranded DNA  
25 (dsDNA), single-stranded DNA (ssDNA) or RNA probes are  
used in a hybridization reaction when oligonucleotide  
sequences are the target.

Nucleic acid probes can be prepared by a variety  
of methods known to those of skill in the art. Purified  
30 double-stranded sequences of DNA (dsDNA) can be labeled  
intact by the process of nick translation or random primer  
extension. The ability of double-stranded probes to  
hybridize to nucleic acids immobilized within cells is  
compromised by the ability of the complementary strands to  
35 hybridize to each other in solution prior to hybridization

1 with the cellular nucleic acids. Single-stranded DNA  
(ssDNA) probes do not suffer this limitation and may be  
produced by the synthesis of oligonucleotides, by the use  
of the single-stranded phage M13 or plasmid derivatives of  
5 this phage, or by reverse transcription of a purified RNA  
template. The use of single-stranded RNA (ssRNA) probes  
in hybridization reactions potentially provides greater  
signal-to-noise ratios than the use of either double or  
single-stranded DNA probes. Regardless of whether a  
10 dsDNA, a ssDNA, or a ssRNA probe is used in the  
hybridization reaction, there must be some means of  
detecting hybrid formation. The means of detecting hybrid  
formation utilizes a probe "labeled" with some type of  
detectable label.

15 Antibody probes are known to those of skill in  
the art. The term "antibody probe" means an antibody that  
is specific for and binds to any target antigen. Such a  
target antigen may be peptide, protein, carbohydrate or  
any other biopolymer to which an antibody will bind with  
20 specificity.

#### Detection Systems

Detectable labels may be any molecule which may  
be detected. Commonly used detectable labels are  
radioactive labels including, but not limited to,  $^{32}\text{P}$ ,  
25  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$  and  $^{35}\text{S}$ . Biotin labeled nucleotides  
can be incorporated into DNA or RNA by nick translation,  
enzymatic, or chemical means. The biotinylated probes are  
detected after hybridization using avidin/streptavidin,  
fluorescent, enzymatic or colloidal gold conjugates.  
30 Nucleic acids may also be labeled with other fluorescent  
compounds, with immunodetectable fluorescent derivatives  
or with biotin analogues. Nucleic acids may also be  
labeled by means of attaching a protein. Nucleic acids  
cross-linked to radioactive or fluorescent histone H1,  
35 enzymes (alkaline phosphatase and peroxidases), or

1 single-stranded binding (ssB) protein may also be used.  
To increase the sensitivity of detecting the colloidal  
gold or peroxidase products, a number of enhancement or  
amplification procedures using silver solutions may be  
5 used.

An indirect fluorescent immunocytochemical  
procedure may also be utilized (Rudkin and Stollar (1977)  
Nature 265: 472; Van Prooijen, et al (1982) Exp.Cell.Res.  
141: 397). Polyclonal antibodies are raised against  
10 RNA-DNA hybrids by injecting animals with  
poly(rA)-poly(dT). DNA probes were hybridized to cells in  
situ and hybrids were detected by incubation with the  
antibody to RNA-DNA hybrids.

According to the present invention single-  
15 stranded probes are preferable. Probes may be directly  
labeled by attachment of an intercalating detectable  
molecule with fluorescers or by covalently-binding to the  
probe such fluorescers. The probe may be labeled with  
more than one molecule of the detectable label.

#### 20 Probe Size and Concentration

The length of a probe affects its diffusion rate,  
the rate of hybrid formation, and the stability of  
hybrids. According to the present invention, to detect  
cellular target RNA, small probes (50-150 bases) yield the  
25 most sensitive, rapid and stable system. A mixture of  
short probes (50-150 bases) are prepared which span the  
entire length of the target biopolymer to be detected.  
For example, if the target biopolymer were 1000 bases  
long, about 10-20 "different" probes of 50-100 bases would  
30 be used in the hybrid solution to completely cover all  
regions of the target biopolymer.

To detect cellular target DNA, even smaller  
probes (15-50 bases) are utilized.

The concentration of the probe affects several  
35 parameters of the in situ hybridization reaction. High

1 concentrations are used to increase diffusion, to reduce  
the time of the hybridization reaction, and to saturate  
the available cellular sequences. According to the  
present invention, the reaction is complete after about 5  
5 minutes. To achieve rapid reaction rates while  
maintaining high signal-to-noise ratios, probe  
concentrations of 1-10 ug/ml are preferable. Most  
preferable is use of probes at a concentration of 2.5  
ug/ml.

#### 10 Hybridization Solution and Temperature

The fixation/hybridization solution of the  
present invention consists of a fixative (described above)  
and a chaotropic agent, typically, 0.8 M LiCl, about 0.1M  
Tris-acetate, pH 7.4, about 50 ug/ml low molecular weight  
15 DNA, and 50 ug/ml ribosomal RNA sized to about 50 bases  
and 0.1% Triton X-100. A single-stranded RNA probe is  
added to this solution prior to the incubations with the  
target cells. The probe may be at least 15-20 bases,  
preferably, 75-150 bases, and labeled with a detectable  
20 label such as a fluorescer. The most preferable optimal  
temperature of hybridization is 50°-55°C. However,  
temperatures ranging from 15°C to 80°C may be used,  
depending on the constituents and concentrations of the  
fixation/ hybridization solution.

#### 25 Post-Hybridization Treatments and Detections

The present invention does not require wash steps  
prior to hybrid detections. If probes are labeled with  
Photobiotin™, then avidin or streptavidin fluorescent,  
enzymatic or colloidal gold complexes may be added  
30 directly to the slides containing hybridization cocktail  
and incubated for 20 minutes at room temperature, or 10  
minutes at 37°C or 5 minutes at 55°C. This step  
constitutes a significant advantage over prior  
hybridization techniques due to the time saved by  
35 eliminating several post-hybridization washing steps and

1 the necessary re-blocking of non-specific  
avidin/streptavidin binding sites; it results in no  
decrease in signal or increase in noise. If probes are  
directly labeled with fluorescers, no additional detection  
5 step is necessary.

Following a streptavidin/avidin detection step or  
directly after the reaction is complete, the specimen is  
washed in large volumes of 2x SSC/0.1% Triton X-100. The  
solution may contain RNase A and T1 at room temperature.  
10 This wash can be very short (about 5 minutes)-as long as a  
continuous gentle circulation or stream of sufficient  
volume (about 200 ml per cm<sup>2</sup> area of cells) of solution  
passes over the cells. This may be followed by washes at  
higher stringency (lower salt concentrations such as at  
15 least 0.1x SSC and/or higher temperatures up to 65° C.).  
Leaving the cell area moist, supports are then dried and  
coverslipped by any conventional method.

## 2. Cells or Tissues in Suspension

### Cells are Prepared

20 Tissue samples are broken apart by physical,  
chemical or enzymatic means into single cell suspension.  
Cells are placed into a PBS solution (maintained to  
cellular osmolality with bovine serum albumin (BSA) at a  
concentration of 10<sup>5</sup> to 10<sup>6</sup> cells per ml. Cells in  
25 suspension may be fixed and processed at a later time,  
fixed and processed immediately, or not fixed and  
processed in the in situ hybridization system of the  
present invention.

### Fixation/Hybridization is accomplished

30 A single solution is added to the cells/tissues  
(hereafter referred to as the specimen). This solution  
contains the following: a mild fixative, a chaotrope, a  
nucleic acid probe (RNA or DNA probe which is prelabeled)  
and/or antibody probe, salts, detergents, buffers, and  
35

1 blocking agents. The incubation in this solution is  
carried out at 55°C for 20 minutes.

5 The fixative is one which has been found to be  
optimal for the particular cell type being assayed (eg.,  
there is one optimal fixative for bone marrow and  
peripheral blood even though this "tissue" contains  
numerous distinct cell types). The fixative is usually a  
combination of precipitating fixatives (such as alcohols)  
and cross-linking fixatives (such as aldehydes), with the  
10 concentration of the cross-linking fixatives kept very low  
(less than 10%). Typically, the solution contains 10-40%  
ethanol, and 5% formalin. The concentration and type of  
precipitating agent and crosslinking agent may be varied  
depending upon the probe and the stringency requirements  
15 of the probe, as well as the desired temperature of  
hybridization. Typical useful precipitating and  
cross-linking agents are specified in Table 1.

TABLE. 1

20

25

30

35

1           The hybridization cocktail contains a denaturing  
agent, usually formamide at 30% (v/v), but other  
chaotropic agents such as NaI, urea, etc. may also be  
used. Furthermore, several precipitating and/or  
5 cross-linking fixatives also have mild denaturing  
properties; these properties can be used in conjunction  
with the primary denaturant in either an additive or  
synergistic fashion. The hybridization cocktail may be  
constructed to preferentially allow only the formation of  
10 RNA-RNA or RNA-DNA hybrids. This is accomplished by  
adjusting the concentration of the denaturing agents along  
with the concentration of salts (primarily monovalent  
cations of the Group I series of metals along with the  
ammonium ion) and along with the temperature of  
15 hybridization which is used. This allows for the selective  
hybridization of probe to either cellular RNA or DNA or  
both RNA and DNA simultaneously with distinct probes.  
This further allows the probes to be supplied in a  
premixed solution which presents the optimal conditions  
20 for generating a signal and minimizing noise while  
simultaneously optimally "fixes" the morphology of the  
cells/tissues.

Hybrids are detected.

25           The probe in the hybridization cocktail may be  
labeled before the hybridization reaction. The label may  
be one of the many types described above. If the probe is  
labeled with Photobiotin™, the hybrids may be detected  
by use of a Streptavidin/Avidin (S/A) conjugated to a  
fluorescent molecule such as FITC, rhodamine, Texas  
30 Red™, etc. or to S/A conjugated to an enzyme or to S/A  
labeled with a heavy metal such as colloidal gold.  
Specifically, a solution containing the streptavidin  
conjugate is added directly to the hybridization cocktail  
over the cells after the end of the hybridization  
35 reaction. The cells are incubated in this solution for 5



1 minutes at 55°C. Longer times of hybridization may be  
used along with both higher or lower temperatures. The  
time of hybridization reaction will vary depending on the  
composition of the hybridization cocktail containing the  
5 fixative (type and concentrations of precipitating agents  
and/or cross-linking agents), buffering agents, pore  
forming agents, denaturing agents and hybrid stabilizing  
agents. Similarly, the temperature may be varied as  
described above.

10 Alternatively, the probes may be directly labeled  
with the fluorescent dye or molecules such as Pontamine  
Sky Blue™ by incubating the nucleic acid probe and dye  
together (1:10 weight:weight proportions) and allowing the  
dye to bind/intercalate. The probe is then precipitated  
15 out of solution and the excess unbound dye is removed by  
repeated washing with 70% ethanol. Probes are also  
labeled directly and covalently by incubation of double  
stranded molecules (RNA-RNA, RNA-DNA, or DNA-DNA) with  
labels which will covalently bind to nucleic acids. After  
20 incubation conditions under which the reaction will take  
place, the strands are separated and each separate strand  
is used as a probe. The concentration of the probe in the  
solution is typically 2.5 ug/ml although a range of  
0.01-10 ug/ml is useful. The probe concentration will  
25 affect the reaction kinetics and may affect the  
sensitivity of the assay along with the signal-to-noise  
ratio.

If the probe is labeled directly with an  
enzymatic label or is detected using an enzymatic or  
30 secondary detectable system, then this reaction may be  
carried out before any wash steps. Following the  
incubation of the specimen with the appropriate buffer for  
the enzyme, the slide is incubated with the substrates for  
the enzyme under conditions specified by the manufacturer  
35 or supplier of the enzyme.

Noise is Washed Away.

1 Cells may be deposited onto slides or centrifuged  
into a pellet following the fixation/hybridization/  
detection reaction(s). Next, the unbound probe is washed  
5 away from the cells by one wash step using a solution of  
0.1 x SSC (1 x SSC = 0.15M NaCl and 0.015 M sodium  
citrate, pH 7.4) with 0.1% Triton X-100™. A total of  
1-200 ml of wash solution may be used per microscope slide  
(i.e., per about 100,000 separated cells or per tissue  
10 section of about 1 square centimeter). The concentration  
and type of the hybrid stabilizing/denaturing agents and  
pore forming agents may be varied depending on the type of  
cells, the type of probe and the acceptable level of  
mismatch of the hybrid.

Results are obtained.

15 When cells are deposited onto slides, results are  
visualized manually on a fluorescent microscope when  
direct or indirectly labeled fluorescent probes are  
utilized. Alternatively, the results may be automatically  
20 analyzed on a fluorescence-based image analysis system  
such as the ACAS 470 Workstation™ which is produced by  
Meridian Instruments. If other types of labels are  
utilized on the probes, the means of detection is varied  
accordingly.

25 When cells are maintained in solution, results  
may be obtained using a flow cytometer to record the  
amount of fluorescence per cell, which represents the  
amount of hybrid per cell. Alternatively, the total  
signal within a cellular sample may be determined using a  
30 device such as a liquid scintillation counter (for  
radioactivity) or a chemiluminescent/fluorescent microtiter  
plate reader for these labels.

1                   Analysis of the Results of In Situ  
                  Hybridizations Speed, Sensitivity and  
                  Quantitation of In Situ Hybridizations

5                   The method of the present invention requires 5  
                  minutes to 4 hours to complete with a sensitivity of as  
                  few as 1-5 molecules of target biopolymers per cell. This  
                  results from the combination of at least three factors: 1)  
                  cellular constituents are not irreversibly precipitated  
                  onto the nucleic acids, 2) the fixation was optimized for  
10                  the particular tissue used, and 3) the kinetics of the  
                  reaction proceed more rapidly at high probe  
                  concentrations, simultaneously with the fixation process  
                  and at elevated temperatures.

15                  The number of copies of mRNA per cell can be  
                  estimated from the number of grains over cells when  
                  radioactive probes are used. With fluorescent or  
                  enzymatic detections a relative estimate of fluorescence  
                  or precipitated colored products allows estimation of mRNA  
                  copy number. Usually, the approximation of copy number is  
20                  easier after manual photography, film processing and  
                  comparisons of photographic prints.

                  The quantitation of radioactive or fluorescent  
                  signals obtained after in situ hybridizations may be  
                  automated by use of an image analysis system such as the  
25                  Meridian ACAS 470 Workstation".

Simultaneous Detection of Multiple Biopolymers

                  The present invention allows simultaneous  
                  detection of different substances (such as mRNAs and  
                  proteins) within the same cells. This may be accomplished  
30                  in one of two ways. First, multiple probes each  
                  containing a unique label (for example, fluorescent tags  
                  "A", "B" and "C" which each emit light at a different  
                  detectable wave length) are all added together in the  
                  hybridization solutions. Alternatively, a hybridization  
35                  and detection reaction may be carried out with one probe

1 and label, residual unreacted probe and label washed away  
under nuclease-free conditions, and another hybridization  
reaction is carried out. This process is repeated as many  
times as desired.

5 Simultaneous Detection of DNA and RNA for the Same Gene

The present invention allows the simultaneous  
detection of DNA and RNA (and protein) for the same gene  
discrimately and concurrently within the same cell. This  
was accomplished in one of two ways. First, multiple  
10 probes each containing a unique label (for example,  
fluorescent tags "A", "B" and "C" which emit light at  
different detectable wavelengths) were all added together  
in the fixation/hybridization solution. Alternatively, a  
fixation/hybridization/detection reaction was carried out  
15 with one probe and label, residual unreacted probe and  
label was washed away under nuclease free conditions and  
another fixation/hybridization reaction was carried out.  
This process was repeated as many times as desired.

When DNA and RNA were both detected, the  
20 selection of the type of probe became important. When the  
cellular target biopolymer is RNA, an anti-sense, single  
stranded DNA probe was used in the assay. If the cellular  
target DNA is the biopolymer to be detected, a  
sense-strand, single-stranded RNA probe would be used in  
25 the assay. This probe selection, and the selection and  
concentration of components of the fixation/hybridization  
solution would allow only RNA-DNA hybrids to be formed.  
Therefore, the probe could only bind to the desired target  
cellular biopolymer; other nucleic acids would inherently  
30 be prevented from interfering with the reaction assay.

The present invention may be provided in the form  
of a kit. The kit of the present invention is used to  
detect the presence of a specific target biopolymer in a  
specimen. Such a kit includes the following:

35

1. A solution containing a fixation/hybridization cocktail and one or more labeled probes. Preferably, this solution will contain 15-40% ethanol, 25-40% formamide, 0-10% formaldehyde, 0.1-1.5 M LiCl, 0.05-0.5 M Tris-acetate (pH 7-8), 0.05%-0.15% Triton X-100, 20 ug/ml-200 ug/ml of a non-specific nucleic acid which does not react with the probe(s), and 0.1 ug/ml to 10 ug/ml of a single stranded probe directly labeled with a reporter molecule. Most preferably, this solution will contain 30% ethanol, 30% formamide, 5% formaldehyde, 0.8M LiCl, 0.1M Tris-acetate (pH 7.4), 0.1% Triton X-100, 50 ug/ml of ribosomal RNA sheared and sized to about 50 bases, and 2.5 ug/ml of a single stranded probe directly labeled with a fluorescent reporter molecule. This solution and the probes would have measurable predefined and identified characteristics and reactivities with cells and target sequences.
2. Means and instructions for performing the said in situ hybridization reaction of the present invention.

Alternatively, the kit may also include:

1. A second detectable reporter system which would react with the probe or the probe-target hybrid.
2. Concentrated stock solution(s) to be diluted sufficiently to form wash solution(s).
3. Any mechanical components which may be necessary or useful to practice the present invention such as a solid support (e.g. a microscope slide), an apparatus to affix

1 cells to said support, or a device to assist  
with any incubations or washings of the  
specimens.

4. A photographic film or emulsion with which  
5 to record results of assays carried out with  
the present invention.

Another version of this kit may include a solution of  
probes encapsulated in liposomes or microspheres, as  
described in Examples 10 and 11.

10 The following examples are offered by way of  
illustration and are not intended to limit the invention  
in any manner. In all examples, all percentages are by  
weight if for solids and by volume if for liquids, and all  
temperatures are in degrees Celcius unless otherwise  
15 noted.

#### EXAMPLE 1

##### Preparation of Probes.

###### A. General.

20 RNA or DNA probes useful in the present  
invention may be prepared according to methods known to  
those of skill in the art or may be obtained from any  
commercial source. RNA probes may be prepared by the  
methods described by Green et al. (1981) Cell 32:681. DNA  
25 probes may be prepared by methods known to those of skill  
in the art such as described by Rigby et al. (1977) J.  
Mol. Biol. 113:237. Synthetic oligonucleotide probes may  
be prepared as described by Wallace et al (1974) Nucleic  
Acids Res. 6: 3543. The probes useful in the present  
30 invention must have the following characteristics:

1. Specific for the target molecule.
2. At least 15 base pairs in length  
and preferably 75-150 base pairs.

1                   B.   Preparation of RNA probes.

                  Sub genomic fragments of the c-myc, c-sis,  
                  or c-abl genes were obtained from Amersham Inc. (Catalogue  
                  nos. RPN.1315X, RPN.1324X, and RPN.1325X, respectively).  
5                   In one embodiment of the present invention, sense strand  
                  probe of the c-myc, c-abl and c-sis genes were utilized.  
                  The c-myc probe used was a 1.3 kb ClaI/EcoRI genomic clone  
                  from the 3' end of the c-myc gene (Dalla-Favera, et al.  
                  (1983) Science 219:963). The c-abl probe was derived from  
10                   a subclone of the human c-abl gene, an EcoRI/Bam HI  
                  fragment corresponding to the 5' c-abl hybridizing region  
                  (de Klein et al. (1982) Nature 300:765). The c-sis probe  
                  was a Bam HI fragment of clone L33 corresponding to the 3'  
                  end of c-sis (Josephs et al. (1983) Science 219:503). The  
15                   HIV and EBV probes were obtained from and prepared as  
                  described in Dewhurst, et al. (1987) FEBS Lett. 213:133.  
                  The CMV probe was described in Gronczol, et al. (1984)  
                  Science 224:159. These template plasmid DNAs were  
                  transcribed as described by Green et al. (1981) Cell 32:  
20                   681. The size and quantity of the RNA were confirmed by  
                  electrophoresis through a denaturing agarose gel as  
                  described by Thomas (1980) Proc. Nat. Acad. Sci. USA 77:  
                  5201 and by spectrophotometric measurement performed at  
                  A<sub>260</sub> and A<sub>280</sub>. A DNA beta-actin probe, prepared as  
25                   described in Cleveland, et. al. (1980) Cell 20:95, and the  
                  RNA probes were labeled with Photobiotin™ as described  
                  by Bresser and Evinger-Hodges (1987) Gene Anal. Tech. 4:  
                  89, incorporated herein by reference. Alternatively,  
                  probes were labeled directly with a fluorescent  
30                   intercalating compound such as ethidium bromide,  
                  mithramycin, Pontamine Sky Blue™, or propidium iodide by  
                  incubating the nucleic acid and dye together overnight at  
                  room temperature in 1:10 (w/w) proportions (nucleic  
                  acid/dye).

35

1           In either labeling method, low-molecular weight  
DNA was added at a concentration of 100 times that of the  
probe, and all polynucleotides were precipitated by the  
addition of 1/3 vol. 10M ammonium acetate and 2-1/2 vol.  
5   of 95% ethanol. The nucleic acids were recovered by  
centrifugation and resuspended in water at a concentration  
of 1 ug/ul of probe and stored at -70°C until used.

C. Preparation of Antibody Probes

Antibody probes specific for antigens such as  
10   viruses or specific determinants thereof, peptides and  
proteins derived from a variety of sources, carbohydrate  
moieties and a wide variety of biopolymers are known to  
those of skill in the art. The methods for preparation of  
such antibodies are also known to those of skill in the  
15   art.

Briefly, polyclonal antibodies may be prepared by  
immunization of an animal host with an antigen.  
Preferably, the antigen is administered to the host  
subcutaneously at weekly intervals followed by a booster  
20   dose one month after the final weekly dose. Subsequently,  
the serum is harvested, antibodies precipitated from the  
serum and detectably labeled by techniques known to those  
of skill in the art.

Monoclonal antibodies may be prepared according  
25   to any of the methods known to those in the art. Fusion  
between myeloma cells and spleen cells from immunized  
donors has been shown to be a successful method of  
producing continuous cell lines of genetically stable  
hybridoma cells capable of producing large amounts of  
30   monoclonal antibodies against target antigens such as, for  
instance, tumors and viruses. Monoclonal antibodies may  
be prepared, for instance, by the method described in U.S.  
Patent No. 4,172,124 to Koprowski, et al. or according to  
U.S. Patent No. 4,196,265 to Koprowski, et al.

35.



1                    Procedures for labeling antibodies are known to  
those of skill in the art.

#### EXAMPLE 2

##### Temperature effect on Hybridization.

5                    K562 cells (ATCC # CCL 243) were grown in Hank's  
Balanced Salt Solution (HBSS) supplemented with 10% fetal  
calf serum. Dividing cells were deposited onto glass  
slides by cytocentrifugation. Cells were fixed/hybridized  
10                   with various concentrations of ethanol (10%, 15%, 20%,  
25%, and 30%), 5% glacial acetic acid, 35% formamide, 5%  
formalin, 0.8M LiCl, 0.1% Triton X-100, 100 ug/ml low  
molecular weight DNA (sheared herring sperm DNA obtained  
from Sigma Chemical Company) and 2.5 ug/ml of either  
15                   c-myc, c-abl or c-sis anti-sense RNA or DNA probes labeled  
with Photobiotin™. The anti-sense RNA probes were  
prepared as described in Example 1. The hybridization  
reactions were carried out at various temperatures ranging  
from 4° to 80° C. After incubation at the desired  
20                   temperatures for two hours, hybrid formation was  
detected. To detect hybridization, streptavidin  
fluorescein or rhodamine complexes at 2x the manufacturer's  
recommended concentration was added to this specimen.  
After incubation at room temperature for 30 min the  
25                   specimens were then gently washed (1 to 200 ml per  
centimeter square of cell area) with 0.1x SSC containing  
0.1% Triton X-100. One drop of a 50/50 (v/v) 100%  
glycerol/2x PBS solution was added to each specimen.  
Using a Nikon fluorescent microscope with photomultiplier  
30                   tube attachments the fluorescence emitted per cell was  
recorded on each slide hybridized at a different  
temperature. Approximately 300 to 800 cells were analyzed  
per slide. Numerical results obtained indicating the  
amount of fluorescence from each cell were graphically

35

1 represented as relative fluorescence verses the  
temperature of hybridization.

The results shown in Figure 1A demonstrate that  
hybridization temperatures of 25°C to 55°C yield the most  
5 relative fluorescence corresponding to the most hybrid  
formation in the present in situ hybridization invention,  
with the above specified reagents and concentrations  
thereof when RNA-DNA hybrids were formed within the  
cells.

10 The results shown in Fig. 1B demonstrate that  
hybridization temperatures of 25°-55° may be used in the  
hybridization reaction when DNA-DNA hybrids are formed  
within the cells.

### 15 EXAMPLE 3

#### Kinetics of In Situ Hybridization.

K562 cells (ATCC # CCL 243) were grown in Hank's  
Balanced Salt Solution (BSS) supplemented with 10% fetal  
calf serum. Dividing cells were deposited onto glass  
20 slides by cytocentrifugation. Cells were fixed/hybridized  
with 30% ethanol, 35% formamide, 5% formalin, 0.8M LiCl,  
0.1% Triton X-100, 100 ug/ml low molecular weight DNA  
(sheared herring sperm DNA obtained from Sigma Chemical  
Company) and 2.5 ug/ml of either c-myc, c-abl or c-sis  
25 anti-sense RNA probe labeled with Photobiotin™. The  
anti-sense RNA probes were prepared as described in  
Example 1.

Figure 2 shows the relationship between the time  
of hybridization and the amount fluorescence signal seen  
30 over cells. The hybridization reactions were carried out  
at various times ranging from 5 minutes to 96 hours.  
After incubation at 55°C for the desired time, hybrid  
formation was detected. To detect hybridization,  
streptavidin fluorescein or rhodamine complexes at 2x the  
35 manufacturer's recommended concentration were added to the

1 specimen. After incubation at room temperature for 30  
minutes the specimens were then gently washed with 0.1x  
SSC/0.1% Triton X-100 at 1-200 ml per cm<sup>2</sup> of cell area.  
One drop of a 50/50 (v/v) 100% glycerol/2x PBS solution  
5 was added to each specimen. Using a Nikon fluorescent  
microscope with photomultiplier tube attachments, the  
fluorescence emitted per cell was recorded on each slide  
hybridized at each different time point. Approximately  
300 to 800 cells were analyzed per slide. Numerical  
10 results obtained indicating the amount of fluorescence  
from each cell were graphically represented as relative  
fluorescence versus the time of hybridization. Figure 2  
demonstrates that the hybridization reaction is  
essentially complete after 5-10 minutes under the  
15 conditions of the present invention.

#### EXAMPLE 4

##### Changes in Secondary Structure Of Cellular RNA.

20 HL60 cells (ATCC # CCL 240) were grown in Hank's  
BSS supplemented with 10% fetal calf serum. Cells were  
harvested and deposited onto glass microscope slides by  
cytocentrifugation. Cells were air dried on glass slides  
and stored at room temperature until used. Cells are  
fixed in one of any number of fixatives for this type of  
25 experiment. Typical fixatives would include 70% ethanol,  
95% ethanol/5% glacial acetic acid, 75% ethanol, 20%  
glacial acetic acid, 100% methanol, 100% acetone, 50%  
acetone, 50% methanol, 4% paraformaldehyde, 2%  
paraformaldehyde, 10% formaldehyde/90% methanol. After  
30 cells were fixed in these fixatives at the appropriate  
time and temperature, slides were removed from the  
fixative and stained with Wright Giemsa or hematoxylin and  
eosin by standard laboratory methods. Cell morphology was  
assessed by comparing the degree of preservation of  
35 morphology after fixation to the morphology prior to

1 fixation. Fixatives which did not effectively retain  
visual morphology were arbitrarily rated as +1. Fixatives  
which effectively retained cellular morphology were  
arbitrarily rated as between +1 and +4 with the most  
5 effective morphologic preservation of cellular morphology  
rated as +4. A second evaluation as to the effective  
preservation of cells by these fixatives was carried out  
when it was desirable to detect cellular antigens. In  
this case, cells were removed from the fixatives and  
10 incubated with an antibody specific for a particular  
target cellular antigen. Again fixatives which  
effectively maintain antigenicity of cellular components  
were arbitrarily rated as +4, while fixatives which did  
not effectively maintain perservation of cellular antigens  
15 were rated lower, the worst as +1. Fixatives which scored  
as +3 or +4 in terms of preservation of cellular  
morphology and/or preservation of cellular antigenicity  
were then used in the following steps. Fresh slides  
containing untreated cells were fixed in these fixatives  
20 and were incubated in hybridization solution containing  
50% formamide, 4x SSC, 0.1 M sodium phosphate, (pH 7.4),  
0.1% Triton X-100, 100 ug/ml low molecular DNA (sheared  
herring sperm DNA obtained from Sigma Chemcial Company).  
No biopolymer probe was included in this solution. The  
25 cells were incubated in hybridization solution at 50°-55°C  
for 5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes. After  
the completion of this hybridization step, cell samples  
were washed gently with 1-200 ml per square centimeter of  
cell area with each of the following solutions containing  
30 0.1% Triton X-100: 2x SSC, 1x SSC, 0.5x SSC, 0.1x SSC.  
The cellular sample was then evaluated as above for  
preservation of cellular morphology and/or preservation of  
cellular antigenicity. The cell sample was then further  
evaluated by staining the cells with 50 ug/ml of propidium  
35 iodide. The propidium iodide will stain double stranded

1 and single stranded nucleic acids within the cell. When  
this dye stains double stranded or single stranded nucleic  
acids it has a different characteristic emission spectra  
upon ultraviolet excitation. An untreated cell sample on  
5 a slide is also stained. The total amount of emitted  
fluorescence is determined on the untreated cell sample  
using a Nikon fluorescence microscope with a  
photomultiplier tube attachment. 300-1000 cells are  
recorded as to the total amount of fluorescence generated  
10 from cytoplasmic double stranded RNA content. This  
measurement then represents a base line level for the  
total fluorescence in the cytoplasm; that is, the total  
RNA in the cytoplasm and that RNA being present in a 100%  
state of double strandedness. The slides which have been  
15 taken through the various fixation and hybridization  
procedures and times are similarly analyzed. In all cases  
it is important to chose a fixation and hybridization  
condition and time which will maintain the same quantity  
of fluorescence in the cytoplasm of the cell. During  
20 hybridization, the fluorescence emitted from the RNA of  
the cytoplasm of the cell due to the staining of the  
propidium iodide will change. The emission pattern  
decreases relative to the double strandedness of the RNA.  
Simultaneously, the wave length emisson which is  
25 reflective of the amount of single stranded RNA in the  
cytoplasm will begin to increase. When the total  
fluorescence in the cytoplasm due to RNA has remained the  
same and the amount of fluorescence due to the amount of  
double stranded RNA in the cytoplasm has decreased  
30 approximately 70% while the amount of fluorescence  
corresponding to the single stranded RNA within the  
cytoplasm has increased an equal value, then conditions  
have been obtained which will allow the detection of 1-5  
molecules of RNA within the cytoplasm. The time of the  
35 hybridization reaction which was required to obtained this

1 shift from double stranded to single strandedness of the  
RNA in the cytoplasm is reflective of the time necessary  
for an actual hybridization reaction to detect 1-5  
molecules per cell of RNA.

5 Specifically, in Figure 3 the relative amount of  
double stranded RNA content is graphically represented on  
the bottom scale. As the RNA in the cytoplasm becomes  
more double stranded, the curves will shift to the right.  
The greater the shift in the amount of double strandedness  
10 to single strandedness of RNA in the cytoplasm, the  
greater the shift of the curves will be from the right to  
the left. The vertical axis represents the cell numbers  
that were counted. In other words if 300-1000 cells were  
counted, the vast majority of them fell within a  
15 particular area of double strandedness. While some cells  
had more double strandedness and some had less double  
strandedness, the analysis can be represented as a bell  
shape curve. On the right hand side of the figure is  
shown the various treatments carried out. The result of  
20 staining untreated cells with propidium iodide is not  
shown. However, after treating HL60 cells with various  
fixatives the amount of double strandedness of cellular  
RNA remained essentially the same. Even if a  
prehybridization treatment is carried out which includes a  
25 protease treatment there is essentially no change in the  
amount of RNA double strandedness. The curve in Figure 3  
corresponding to the protease treatment is in the same  
location as the curve for the fixation treatment. It has  
shifted neither left nor right. However, after fifteen  
30 minutes in a hybridization solution, the curve  
representing the amount of RNA double strandedness has  
shifted at least 70% to the left. This corresponds to a  
change in at least 70% of the amount of material in the  
cytoplasm of the cell becoming single stranded. Comparing  
35 this graph to Figure 2 indicates that after 15 min in the

1 hybridization cocktail, not only is 70% of the RNA in the  
cytoplasm of the cell single stranded, but as seen in  
Figure 2, 70% of the hybridization reaction is complete.

#### 5 EXAMPLE 5

##### Detection of Oncogenes in Peripheral Blood Cells

10 Ten ml of human peripheral blood cells were  
incubated at 37°C in a 1.2% (215 mOs) ammonium oxalate  
solution to lyse the red blood cells. The white blood  
cells were centrifuged at 3,000 rpm for 10 minutes in a  
clinical centrifuge. The cell pellet was subsequently  
washed with 10 ml. PBS and the pellet was resuspended in  
15 PBS. Cells were deposited by cytocentrifugation onto  
precleaned glass slides and air dried for 5 min. The  
cells were then fixed and hybridized in a solution  
consisting of 30% ethanol/1% glacial acetic acid, 30%  
formamide, 0.8M LiCl, 0.1M Tris-acetate (pH 7.4), 0.1%  
Triton X-100, 100 ug/ml low molecular weight DNA (sheared  
20 herring sperm DNA obtained from Sigma Chemical Co.) and  
2.5 ug/ml of either c-myc, c-sis, c-abl, anti-sense RNA  
probes labeled with Pontamine Sky Blue™. The antisense  
RNA probes were prepared as described in Example 1. After  
incubation for 10 min. at 55°C, hybrid formation was  
25 detected.

The specimens were then gently washed (1-200 ml  
per cm<sup>2</sup> of cell area) with a solution containing 0.1%  
Triton X-100, 0.1x SSC. One drop of a 50/50 (v/v) 100%  
glycerol/2x PBS solution was added to each specimen.  
30 Specimens were photographed with high speed film (Kodak  
EES135, PS 800/1600) at 1600 ASA for 5 sec. exposure on a  
Nikon Photophot microscope at 400x magnification using a  
standard filter combination for transmission of  
fluorescent light.

1           Figure 4 depicts the results from in situ  
hybridization studies on the expression of three different  
oncogenes in peripheral blood (PB). Fig. 4A demonstrates  
the detection of the c-abl gene. Panel B shows the  
5       results of in situ hybridization with a c-sis probe.  
Panel C presents a typical result when the cells were  
hybridized with the c-myc probe.

#### EXAMPLE 6

##### Oncogene Detection in Solid Tissue.

10           Four micron thick frozen sections of human  
breast tissue obtained from surgically removed biopsy  
samples were mounted on precleaned glass slides.

15           Tissue was fixed and hybridized for 20 minutes by  
incubation at 55°C with a fixation/hybridization (One  
Step) cocktail, containing 20% ethanol, 30% formamide,  
0.8M LiCl, 0.1M Tris-acetate (pH 7.4), 50 ug/ml of low  
molecular weight denatured herring sperm DNA, 50 ug/ml of  
ribosomal RNA sheared and sized to 50 bases, and 0.1%  
20       Triton X-100. Pontamine Sly Blue™ labeled RNA probes (as  
described in Example 1) were added to the hybridization  
cocktail at a concentration of 2.5 ug/ml. No probe was  
added to the "blanks". Slides were washed at room  
temperature in 2x SSC containing 0.1% Triton X-100, 100  
25       ug/ml RNase A (Sigma), and sequentially diluted SSC  
solutions until the final wash in 0.1x SSC (1-200 ml per  
CM<sup>2</sup> of cell area).

30           Detection of the labeled probes was performed by  
photography with a Nikon Photophot microscope with  
fluorescence capabilities using Kodak Ektachrome EES-135  
(PS 800/1600) film, exposed and push processed at 1600  
ASA. A 10 second exposure time was consistently used to  
allow direct comparison of one photograph to another.

35           Figure 5 demonstrates the results of the mRNA in situ  
hybridization assay and the localization of



1 SIS/PDGF-B expression in the epithelial components of  
breast carcinoma (Fig. 5, panel SIS-AS). An in situ  
hybridization reaction with the anti-sense c-myc RNA probe  
was used as positive control (Fig. 5 Panel MYC); in situ  
5 hybridization with the sense strand c-sis RNA probe (Fig.  
5 panel SIS-S) was used as a negative control. Comparable  
histologic features are shown in the far right panel. Two  
cases of infiltrating ductal carcinoma are illustrated.

#### 10 EXAMPLE 7

##### Detection of HIV in Human Peripheral Blood.

Ten ml of human peripheral blood was incubated at  
37°C in a 1.2% ammonium oxalate solution to lyse the red  
blood cells. The white blood cells were centrifuged at  
15 3,000 rpm for 10 minutes in a clinical centrifuge. The  
cell pellet was subsequently washed with 10 ml PBS and the  
pellet was resuspended in PBS. Cells were deposited by  
cytocentrifugation onto precleaned glass slides and air  
dried for 5 min. The cells were then fixed and hybridized  
20 in a solution consisting of 25% ethanol, 30% formamide, 5%  
formalin, 0.8 M LiCl, 0.1M Tris-acetate (pH 7.4), 0.1%  
Triton X-100, 100 ug/ml low molecular weight DNA (sheared  
herring sperm DNA obtained from Sigma Chemical Co.) and  
2.5 ug/ml of either HIV anti-sense or sense strand RNA  
25 probes labeled with Pontamine "Sky Blue". The RNA probes  
were prepared as described in Example 1. After incubation  
for 10 min. at 55°C, hybrid formation was detected.

The specimens were then gently washed (1-200 ml  
per cm<sup>2</sup> of cell area) with the following solution: 0.1%  
30 Triton X-100/ 0.1x SSC. One drop of a 50/50 (v/v) 100%  
glycerol/2x PBS solution was added to each specimen prior  
to coverslipping the specimen and microscopic  
examination. Specimens were photographed with high speed  
film (Kodak EES135, PS 800/1600) at 1600 ASA for 5 sec.  
35 exposure on a Nikon Photophot microscope at 400x

1 magnification using a standard filter combination for  
transmission of fluorescent light. Fig. 6 demonstrates  
the detection of HIV sequences in human peripheral blood.  
Fig. 6, panel AS-HIV demonstrates hybridization with a  
5 cocktail containing anti-sense HIV RNA probes; Fig. 6  
panel S-HIV demonstrates that no hybridization is  
detectable using sense HIV RNA probes. The present in  
situ hybridization invention detected HIV in a virus  
infected patient, while the negative controls were blank.

10

#### EXAMPLE 8

##### Quantitation of the Number of Target Biopolymer Molecules.

K562 Cells (ATCC #CCL 243) were grown in Hank's  
BSS supplemented with 10% fetal calf serum. Three days  
15 after the last change in media, the cells were split to a  
density of about  $10^5$  cells per 0.3 ml. of fresh media.  
One hour later, 60 replica slides were made by depositing  
50,000-100,000 cells onto a slide by cytocentrifugation.  
The remainder of the cells were harvested and RNA and DNA  
20 was extracted from the cells by the guanidium cesium  
chloride method (GuSCN/Cscl) (Chirgwin, et al. (1979)  
Biochemistry 18: 5294).

Since the cell line was a relatively homogeneous  
population, the extracted RNA was purified and used to  
25 determine copy number estimates for each RNA species  
analyzed; i.e., an estimate could be made of the number of  
molecules of each gene present within each cell from a  
series of control experiments well known to those with  
knowledge and skill in the art. These control experiments  
30 to determine the number of molecules per cell included the  
following: Northern blots, RNA dot blots, Quick-blots™,  
Cytodots™, single copy saturation experiments, and  
solution concentration versus time hybridization  
experiments (Rot<sub>1/2</sub> analysis) (Hames, B.D. and Higgins,

35

1 S.J. (1986) in Nucleic Acid Hybridization: a practical approach, IRL Press, Oxford-Washington, D.C.).

Cells on slides were fixed and hybridized in a solution consisting of 25% ethanol, 30% formamide, 5% formalin, 0.8 M LiCl, 0.1 M Tris-acetate (pH 7.4), 0.1% Triton X-100, 100 ug/ml low molecular weight DNA (sheared herring sperm DNA obtained from Sigma Chemical Co.) and 2.5 ug/ml of an anti-sense RNA probe labeled with Pontamine Sky Blue™. Probes used were either the sense or anti-sense RNA strands of the following genes: c-abl, c-sis, c-myc, or Epstein Barr Virus (EBV). The probes were prepared as described in Example 1. After incubation for 10 min. at 55°C, hybrid formation was detected.

15 The specimens were then gently washed (1-200 ml. per cm<sup>2</sup> of cell area) with 0.1x SSC containing 0.1% Triton X-100. One drop of a 50/50 (v/v) 100% glycerol/2x PBS solution was added to each specimen and a #1 coverslip was placed over the cells before microscopic examination.

Fluorescence emitted from each cell is a reflection of the number of fluorescent molecules which reacted with and attached to the probe; the amount of reacted probe within a cell is indicative of the number of target biopolymers present within the cell. To measure the fluorescence within each cell, slides were analyzed using the ACAS 470 Workstation™ from Meridian Instruments (Okemos, MI). The Meridian instrument, like most image processing systems, excites the fluorescers present within a sample and then captures the emitted light as either a digital or analog signal. This signal is digital on the Meridian instrument. The quantity of the signal can be represented by different colors. In Figure 7, this is illustrated by the colors the instrument assigns to emitted signals of different intensities. When these colors are represented over a cell, as in Figure 7,

35

1 the amount and subcellular location of the target cellular  
biopolymer and the hybridized probe can be seen.

The total amount of fluorescent signal per cell  
can also be detected and analyzed. From the control  
5 experiments carried out above to determine the number of  
molecules of mRNA corresponding to different genes within  
the K562 cells, known values (minimums, maximums, averages  
and standard deviations) are obtained for the number of  
molecules of each type of RNA per cell. These values are  
10 used as inputted data in the Meridian instrument's analysis  
of data, and are seen as the horizontal axis of Figure 8.  
The vertical axis is the number of cells. The different  
columns represent the number of cells (vertical axis)  
possessing a given number of molecules (horizontal axis)  
15 of the target biopolymer. Figure 8 demonstrates that the  
c-myc gene mRNA was present at the lowest level in the  
K562 cells (about 1-10 molecules). The c-sis gene mRNA  
was present at about 1-20 molecules. The c-abl gene mRNA  
was present in a much higher number of molecules per cell  
20 ranging from about 20-55 molecules.

#### EXAMPLE 9

##### In Situ Hybridization of mRNA Within Cells in Suspension

25 K562 cells (ATCC # CCL 243) were grown in Hank's  
Balanced Salts Solution (HBSS) supplemented with 10% fetal  
calf serum. Three days after the last medium change, the  
cells were split to a density of about  $10^5$  cells per 0.3  
ml of fresh medium. One hour later, cells were pelleted  
30 at 3000 rpm in a clinical centrifuge and resuspended at a  
concentration of  $10^5$  to  $10^6$  cells per ml in HBSS  
without serum. The cells were then processed by one of  
the following methods:

35

1. Cells were fixed.

Cells were fixed in solution consisting of 45% ethanol/5% formalin. This was done by adding an equal volume of a solution of 90% ethanol/10% formalin to the cell sample. Cells may be stored in this solution at 4°C for at least several days. To carry out the in situ hybridization reaction, an equal volume of a solution consisting of 60% formamide, 4 M ammonium acetate, 0.2 M Tris-acetate (pH 7.4), 100 ug/ml of ribosomal RNA sheared and sized to 50 bases, and 5 ug/ml of an RNA probe directly labeled with fluorescein, prepared and labeled as described in Example 1, was added to the cell suspension. After incubation at 55°C for 30 minutes, the cells were pelleted by centrifugation at 3000 rpm in a clinical centrifuge. The cell pellet was washed three times with HBSS. In the final wash, the cells were resuspended at about 75,000 cells per 0.3 ml. The detection of hybrid formation was accomplished after the cells were deposited onto glass slides by cytocentrifugation. One drop of a 50/50 (v/v) 100% glycerol/2x PBS solution was added to each specimen and a #1 coverslip was placed over the cells before microscopic examination. Alternatively, flow cytometer instrumentation could also be used for the detection of hybrid formation.

Fluorescence emitted from each cell is a reflection of the number of fluorescent molecules which reacted with or were attached to the probe; the amount of reacted probe within the cells was therefore visualized and recorded through photomicroscopy using a Nikon Photophot fluorescence microscope. Specimens were photographed with high speed film (Kodak EES135, PS 800/1600) at 1600 ASA for 10 seconds exposure time and a 400x magnification using standard filter combinations for transmission of fluorescent light.

1           The results are demonstrated in Fig. 9, panels  
2           1-4. It is known that K562 cells express mRNA target  
3           nucleic acid sequences corresponding to the c-abl, c-sis,  
4           and c-myc oncogenes. The detection of the c-abl gene is  
5           shown in panel 1, as the light emitted from the cells; the  
6           detection of the c-sis gene is shown in panel 2, and the  
7           detection of the c-myc gene in panel 3. Panel 4 shows  
8           that the background is negative when no probe is included  
9           in the in situ hybridization reaction.

10          2. Cells were not fixed before the in situ  
11          hybridization assay.

12          To carry out the in situ hybridization reaction,  
13          an equal volume of the following solution was added to the  
14          cell suspension: a solution consisting of 35% ethanol,  
15          55% formamide, 5% formalin, 4 M ammonium acetate, 0.2 M  
16          Tris-acetate (pH 7.4), 100 ug/ml of ribosomal RNA sheared  
17          and sized to 50 bases, and 5 ug/ml of an anti-sense RNA  
18          probe directly labeled with fluorescein, prepared and  
19          labeled as described in Example 1. After incubation at  
20          37° C for 20 minutes, the cells were pelleted by  
21          centrifugation at 3000 rpm in a clinical centrifuge. The  
22          cell pellet was washed three times with HBSS. In the  
23          final wash, the cells were resuspended at about 75,000  
24          cells per 0.3 ml. The detection of hybrid formation was  
25          accomplished after the cells were deposited onto glass  
26          slides by cytocentrifugation. One drop of a 50/50 (v/v)  
27          100% glycerol/2x PBS solution was added to each specimen  
28          and a #1 coverslip was placed over the cells before  
29          microscopic examination. Alternatively, instrumentation  
30          could also be used for the detection of hybrid formation  
31          such as a flow cytometer.

32          Fluorescence emitted from each cell is a  
33          reflection of the number of fluorescent molecules which  
34          reacted with probe; the amount of reacted probe within the  
35          cells was therefore visualized and recorded through

1 photomicroscopy using a Nikon Photophot fluorescence  
microscope. Specimens were photographed with high speed  
film (Kodak EES135, PS 800/1600) at 1600 ASA for 10  
seconds exposure time and at 400x magnification using  
5 standard filter combinations for transmission of  
fluorescent light.

The results are demonstrated in Figure 9, panels  
5-8. It is known that K562 cells express mRNA target  
nucleic acid sequences corresponding to the c-abl, c-sis,  
10 and c-myc oncogenes. The detection of the c-abl gene is  
shown in panel 5, as the light emitted from the cells; the  
detection of the c-sis gene is shown in panel 6, and the  
detection of the c-myc gene in panel 7. Panel 8 shows  
that the background is negative when no probe is included  
15 in the in situ hybridization assay.

#### EXAMPLE 10

##### In Situ Hybridization of mRNA within Cells in Suspension: Hybridization to 20 HIV Sequences Within Viable Cells

The T-cell derived cell line H9 (ATCC # CRL 8543)  
containing the pBH10 strain of HIV, the cell line K562 and  
the cell line HL60 were separately grown in medium  
consisting of Hank's Balanced Salt Solution supplemented  
25 with 10% fetal calf serum. Three days after the last  
change in media, the cells were split to a density of  
about  $10^5$  cells per 0.3 ml of fresh media. One hour  
later, cells were pelleted at 3000 rpm in a clinical  
centrifuge and resuspended at a concentration of  $10^5$  to  
30  $10^6$  cells per ml in HBSS without serum.

HIV anti-sense or sense RNA probes were prepared  
as described in Example 1 and labeled with  
Photobiotin™. The probes were then encapsulated into  
reverse evaporation phase liposome vesicles (REVs)  
35 according to the method of Szoka (1978) Biochemistry 75:

1 4194. The liposomes were sterile filtered and stored at  
4°C for up to four weeks before use.

To carry out the in situ hybridization reaction,  
the REVs were added to the cell sample and a 30 minute or  
5 60 minute incubation was carried out at 55°C or 37°C,  
respectively. The cells were then pelleted by  
centrifugation at 3000 rpm for 10 minutes. The cell  
pellet was washed once with HBSS, pelleted again, and  
resuspended in HBSS supplemented with 10% serum; the cells  
10 were then allowed to continue to grow at 37°C in an  
atmosphere of 5% CO<sub>2</sub> in air.

If the probes which were added to the cells had  
recognized and bound to a specific target cellular gene  
corresponding to the HIV virus, the function of that  
15 cellular target gene should be altered. To assay for the  
successfulness of the probe binding to a target viral  
sequence within a living cell, specific biological  
properties associated with the presence of active virus  
within a cell were assayed. The results of these  
20 biological assays are summarized on Table 2. H9 cells  
containing the pBH10 isolate of HIV were used as positive  
controls (HIV+). Uninfected H9 cells, HL60 cells and K562  
cells were all used as negative controls (HIV-). No  
differences were seen between the 3 negative control cell  
25 lines with respect to any property tested. Syncytia  
formation was scaled after microscopic examination on a  
relative basis: -, no detectable syncytia; +, some  
detectable syncytia; +++, many syncytia seen. Changes in  
viral reverse transcriptase activity were measured  
30 relative to cells receiving no probe. HIV viral antigens  
were detected by indirect immunofluorescence. Antibodies  
directed to these antigens were supplied by Cellular  
Products, Inc. RNA and DNA were prepared by the  
GuSCN/CsCl method. Dot blots were prepared and hybridized  
35 to <sup>32</sup>P-labeled double stranded DNA (ds-DNA) full length



1 genomic probes. Hybridizations and wash conditions were  
stringent enough only to exclude detection of rRNA and  
other human endogenous retroviral sequences. Filters were  
5 exposed to film for a sufficient period of time to detect  
single copy sequences. Scoring was based on an arbitrary  
scale with infected H9 cells as an upper level control  
(+++).

The REVs containing the anti-sense HIV probes are  
referred to on the table as "Drug". The REVs containing  
10 negative control sense strand HIV probes are referred to  
on the table as "Drug Analog". REVs which contained no  
probe are referred to on the table as "No Drug".

TABLE 2

15

20

25 Table 2 summarizes the results demonstrating that the in  
situ hybridization procedure can introduce and cause  
hybrid formation between a probe and a specific target  
mRNA sequence and that the introduced anti-sense probe  
will inhibit the activity of the target mRNA. These  
30 biological assays included the inhibition of syncytia  
formation, the inhibition of viral enzymes and proteins as  
well as the detection of viral RNA and DNA. Syncytia  
formation is a process wherein virus infected cells will  
tend to clump together into very large apparently  
35 multinucleated masses. The absence of syncytia formation

1 in the "Drug" treated cells indicated that the probe was  
delivered to and hybridized with the specific cellular  
target sequences, thereby blocking the formation of  
syncytia. The enzyme reverse transcriptase is a virus  
5 specific enzyme. The greater than 99% decrease in the  
activity of this enzyme in virus infected cells, along  
with the lack of production of other viral proteins also  
demonstrates the successful inhibition of the expression  
of the viral phenotype by the hybridization of the  
10 anti-sense RNA probe to the cellular mRNA of the infected  
cells.

#### EXAMPLE 11

In Situ Hybridization of mRNA within  
15 Cells in Suspension: Hybridization to HIV  
Sequences Within Cells from Virus Infected Patients.

Ten ml of human peripheral blood from patients  
with AIDS, AIDS-related complex (ARC) or asymptomatic  
sero-positive individuals was diluted with twenty ml of  
20 HBSS and layered over a Ficoll-Hypaque™ solution. The  
sample was centrifuged to separate the mononuclear cells.  
These cells were removed and placed into sterile culture  
with growth medium consisting of HBSS supplemented with  
10% human serum/5% fetal calf serum. The medium was  
25 replaced after three days in culture. The cell lines K562  
and HL60 were each grown in culture in HBSS containing 10%  
fetal calf serum. Three days after the last change in  
media, the cells were split to a density of about  $10^5$   
cells per 0.3 ml of fresh medium. One hour later, cells  
30 were pelleted at 3000 rpm in a clinical centrifuge and  
resuspended at a concentration of  $10^5$  to  $10^6$  cells per  
ml in HBSS without serum.

HIV anti-sense or sense RNA probes were prepared  
as described in Example 1 and labeled with  
35 Photobiotin™. The probes were then encapsulated into

1        reverse evaporation phase liposome vesicles (REVs)  
      according to the method of Szoka (1978) Biochemistry 75:  
      4194. The liposomes were sterile filtered and stored at  
      4°C for up to four weeks before use.

5                To carry out the in situ hybridization reaction,  
      the REVs were added to the cell sample and a 30 minute or  
      a 60 minute incubation was carried out at either 55°C or  
      37°C, respectively. The cells were then pelleted by  
10        centrifugation at 3000 rpm for 10 minutes. The cell  
      pellet was resuspended in HBSS supplemented with 10% serum  
      and the cells were allowed to continue to grow.

      When the probes are added to cells and bind to a  
      specific target cellular gene within the cells  
      corresponding to the HIV virus, the function of that  
15        cellular target gene is altered. To assay for the  
      successfulness of the probe binding to a target viral  
      sequence within a living cell, specific biological  
      properties associated with the presence of active virus  
      within a cell were assayed. The results of these  
20        biological assays are summarized on Table 3. The REVs  
      containing the anti-sense HIV probes are referred to on  
      the table as "Drug". The REVs containing negative control  
      sense strand HIV probes are referred to on the table as  
      "Drug Analog". REVs which contained no probe are referred  
25        to on the table as "No Drug". Table 3 summarizes the  
      biological observation which documented that the present  
      invention was capable of introducing and causing hybrid  
      formation between a probe and a specific target mRNA  
      sequence. These biological assays included the  
30        observation of whether cells formed syncytia. Since HIV  
      realted viruses tend to inhibit cell proliferation, the  
      increase in cell proliferation with the "Drug" treatment  
      further demonstrated the success of delivery of the RNA  
      probes to and hybridization with the mRNA in viable  
35        cells. The enzyme reverse transcriptase is a virus

1 specific enzyme. The greater than 93% decrease in the  
activity of this enzyme in virus infected cells, along  
with the lack of production of other viral proteins also  
demonstrates the successful inhibition of the viral  
5 phenotype expression.

Fig. 10 demonstrates that cells which do not  
contain the matching target sequences for the REV  
contained probe are not altered as to their DNA content by  
the present invention. Fig. 10 shows the results of a  
10 Southern blot of K562 cells treated with the REVs  
containing sense strand probes (Lanes A1 and B1) or REVs  
containing anti-sense strand probes (Lanes A2 and B2).  
The third lane on both the A and B columns is a positive  
control known to contain sequences which would react with  
15 either the sense or anti-sense strand probes. This  
demonstrates that the probe was degraded and does not  
cause a change in the cellular DNA when the REV delivered  
the probe to a cell which did not contain a matching  
target sequence.

20 Fig. 11 demonstrates that cells which do not  
contain the matching target sequences for the REV  
contained probe were not altered as to their RNA content.  
In the top (HIV) panel, K562 cells which were treated with  
the sense probe (Lane A) or with the anti-sense probe  
25 (Lane B) did not contain any new cellular RNA  
corresponding to the probe or its complementary match.  
The third lane (C) demonstrates a positive control known  
to contain sequences which would react with either the  
sense or anti-sense strand probes, demonstrating that the  
30 probe is degraded and does not cause a change in the  
cellular RNA when the REV delivered the probe to a cell  
which did not contain a matching target sequence.

TABLE 3

1

5

10

EXAMPLE 12Detection of HIV and CMV in Human Peripheral Blood

Ten ml of human peripheral blood from a patient with Kaposi Sarcoma was incubated at 37°C in a 1.2% ammonium oxalate solution to lyse the red blood cells. The white blood cells were centrifuged at 3,000 rpm for 10 minutes in a clinical centrifuge. The cell pellet was subsequently washed with 10 ml PBS and the pellet was resuspended in PBS. A number of replica slides were prepared by depositing 50,000-100,000 cells by cytocentrifugation onto precleaned glass slides. To these cells was added 20 ul of hybridization solution consisting of 30% ethanol, 30% formamide, 5% formaldehyde, 0.8M LiCl, 0.1M Tris-acetate (pH 7.4), 100 ug/ml low molecular weight DNA, 0.1% Triton X-100 and 2.5 ug/ml hybrid mix of either four HIV anti-sense or sense RNA probes or a CMV anti-sense RNA probe directly labeled with Pontamine Sky Blue™. The RNA probes were prepared as described in Example 1. After incubation for 10 min. at 55°C, the specimens were gently washed (1-200 ml per cm<sup>2</sup> of cell area) with 0.1x SSC containing 0.1% Triton X-100. One drop of a 50/50 (v/v) 100% glycerol/2x PBS solution was added to each specimen. Specimens were photographed with high speed film (Kodak EES135, PS 800/1600) for 5 sec. exposure on a Leitz microscope at 400x magnification using

1 a standard filter combination for transmission of  
fluorescent light.

Figure 12, panel "BLANK" represents the results  
when no probe was added to the hybridization solution;  
5 panel "HIV", when four anti-sense strand HIV probes were  
added; panel "SENSE", when four sense strand HIV probes  
were added; and panel "CMV", when an anti-sense CMV probe  
was added. Two viruses (HIV and CMV) associated with HIV  
infection in Kaposi sarcoma were detected by the one-step  
10 in situ hybridization of the present invention.

### EXAMPLE 13

#### Detection of Oncogenes in the K562 Cell Line

K562 cells (ATCC #CCL 243) were grown in HBSS  
15 supplemented with 10% fetal calf serum. One hour after  
the medium was changed, a number of replica slides were  
prepared by depositing 50,000-100,000 cells onto a slide  
by cytocentrifugation. To these cells was added twenty  $\mu$ l  
of hybridization solution consisting of 20% ethanol, 30%  
20 formamide, 5% formaldehyde, 0.8M LiCl, 0.1M Tris-acetate  
(ph 7.4), 100  $\mu$ g/ml low molecular weight DNA, 0.1% Triton  
X-100 and 2.5  $\mu$ g/ml of either a c-myc, c-sis, or c-abl  
anti-sense RNA probe labeled directly with Pontamine Sky  
Blue™. The probes were prepared as described in Example  
25 I. After incubation for 10 minutes at 55°C, the specimens  
were gently washed (1-200 ml per  $\text{cm}^2$  of cell area) with  
0.1x SSC containing 0.1% Triton X-100. One drop of a  
50/50 (v/v) 100% glycerol/2x PBS solution was added to  
each specimen and a #1 coverslip was placed over the cells  
30 before microscopic examination. Photographs were obtained  
as described in Example 12.

Figure 13, panel D demonstrates the results when  
no probe was added to the hybridization solution; panel A,  
when c-abl anti-sense probe was added; panel C, when c-myc  
35 anti-sense probe was added; and panel B, when c-sis

1 anti-sense probe was added. The one-step in situ  
hybridization procedure of the present invention detected  
3 oncogenes known to be expressed in this cell line. The  
negative control (panel D) is blank.

5 One skilled in the art will readily appreciate  
that the present invention is well adapted to carry out  
the objects and obtain the ends and advantages mentioned,  
as well as those inherent therein. The components,  
methods, procedures and techniques described herein are  
10 presently representative of the preferred embodiments, are  
intended to be exemplary, and are not intended as  
limitations on the scope of the present invention.  
Changes therein and other uses will occur to those skilled  
in the art which are encompassed within the spirit of the  
15 invention and are defined by the scope of the appended  
claims.

What is claimed is:

20

25

30

35

1           1.    A method for assaying biopolymers in a  
specimen having substantially intact membranes comprising  
the steps of:

5                   contacting said sample with a medium  
comprising a precipitating agent, a cross-linking  
agent, a denaturing agent, a hybrid stabilizing  
agent, a buffering agent, a selective membrane  
pore-forming agent and at least one probe having  
a nucleotide sequence at least substantially  
10               complementary to a specific nucleotide sequence  
to be detected, said contacting being under  
hybridizing conditions,

15                   incubating said sample with said medium in  
the presence of at least one energy emitting  
label,

20                   detecting duplex formation by means of said  
label, wherein said method is capable of  
detecting at least 1 to at least 5 biopolymers  
per cell.

2.    The method of Claim 1 wherein said label is  
attached to said probe.

25           3.    The method of Claim 1 wherein said label is  
added after the duplex formation is complete.

30           4.    The method of Claim 1 wherein said label is  
selected from the group consisting of fluorescers,  
chemiluminescers, enzyme labels, and radiolabels.

35           5.    The method of Claim 3 wherein said label is  
selected from the group consisting of avidin and  
streptavidin.



1           6.    The method of Claim 1 wherein said  
precipitating agent is selected from the group consisting  
of ethanol, methanol, acetone, formaldehyde and  
combinations thereof.

5           7.    The method of Claim 1 wherein said  
cross-linking agent is selected from the group consisting  
of paraformaldehyde, formaldehyde, dimethylsilserimide,  
and ethyldimethylamino-propylcarbodiimide.

10          8.    The method of Claim 1 wherein said  
denaturing agent is selected from the group consisting of  
formamide, urea, sodium iodide, thiocyanate, guanidine,  
perchlorate, trichloroacetate, and tetramethylamine.

15          9.    The method of Claim 1 wherein said hybrid  
stabilizing agent is selected from the group consisting of  
sodium chloride, lithium chloride, magnesium chloride,  
ferric sulfate and ammonium acetate.

20          10.   The method of Claim 1 wherein said pore  
forming agent is selected from the group consisting of  
Brij 35, Brij 58, Triton X-100, CHAPS™, desoxycholate  
and sodium dodecyl sulfate.

25          11.   The method of Claim 1 wherein said  
biopolymer is RNA.

30          12.   The method of Claim 1 wherein said  
biopolymer is DNA.

35          13.   The method of Claim 1 wherein said  
biopolymer is an antigen.

1           14. The method of Claim 1 wherein at least two  
biopolymers are assayed simultaneously in the same  
sample.

5           15. The method of Claim 14 wherein at least one  
biopolymer is a polynucleotide and a second biopolymer is  
an antigen.

10           16. The method of Claim 1 wherein said  
temperature is 15°C- 80°C.

          17. The method of Claim 16 wherein said  
temperature is 50°C to 55°C.

15           18. The method of Claim 1 wherein said method is  
accomplished within about 4 hours.

          19. The method of Claim 1 wherein said  
biopolymer is selected from the group consisting of a RNA,  
20       a DNA, a viral gene, an oncogene, and an antigen.

          20. The method of claim 1, wherein said  
biopolymer is an oncogene.

25           21. The method of claim 1, wherein said  
biopolymer is a virus.

          22. A kit for assaying the presence of a  
biopolymer in a suspect cell sample comprising,  
30       a hybridization solution comprising a  
precipitating agent, a cross-linking agent, a  
denaturing agent, a hybrid stabilizing agent, a  
buffering agent, and a selective membrane  
pore-forming agent.

35

1           23. The kit of claim 22 also comprising,  
a supply of a probe selected so that it will  
hybridize with said suspect biopolymer if it is  
present, to form a hybridized complex.

5           24. The kit of claim 23 also comprising,  
means for contacting said suspect sample  
with said probe to form said hybridized complex,  
and

10               means for measuring for the presence and/or  
extent of the presence of such labeled probe.

25. The kit of claim 23 where in said probe is  
detectably labelled.

15           26. The kit of claim 23 also comprising,  
a detectable label capable of detecting hybrid  
formation.

20           27. A kit for assaying the presence of a  
biopolymer in a suspect cell sample comprising,  
a hybridization solution comprising 30% ethanol,  
30% formamide, 5% formaldehyde, 0.8M LiCl, 0.1M  
Tris-acetate (pH 7.4), 0.1% Triton X-100,  
25           50 ug/ml of ribosomal RNA sheared and sized to  
about 50 bases, and 2.5 ug/ml of a single  
stranded probe directly labeled with a  
fluorescent reporter molecule.

30           28. The kit of claim 27 also comprising,  
a supply of a probe selected so that it will  
hybridize with said suspect biopolymer if it is  
present, to form a hybridized complex.

35

1           29. The kit of claim 28 wherein said probe is  
detectably labeled.

5           30. The kit of claim 28 also comprising,  
a detectable label capable of detecting hybrid  
formation.

10           31. The method of claim 1 wherein said detecting  
of hybrid formation is quantitative.

15

20


25

30

35

1 / 14


# Effect of Temperature on Hybridizations in Fixation/Hybridization Cocktail



SUBSTITUTE SHEET

2/14


# Effect of Temperature on Hybridizations in Fixation/Hybridization Cocktail



SUBSTITUTE SHEET

3/14


# Kinetics of Hybridization with DNA or RNA Probes in Fixation/Hybridization Cocktail



SUBSTITUTE SHEET

4 / 14

# SECONDARY STRUCTURE OF CELLULAR RNA



SUBSTITUTE SHEET



5/14



FIG. 4C



FIG. 4B




FIG. 4A

SUBSTITUTE SHEET

6/14

BLANK

SIS-S

MYC

SISAS

FIG. 5

SUBSTITUTE SHEET

7/14




FIG. 6

SUBSTITUTE SHEET

8/14




FIG. 7

SUBSTITUTE SHEET




FIG. 8

SUBSTITUTE SHEET

10/14




FIG. 9

SUBSTITUTE SHEET






FIG. 10A


FIG. 10B

SUBSTITUTE SHEET




SUBSTITUTE SHEET





**FIG. 12**  
SUBSTITUTE SHEET

14/14



**FIG. 13**

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/03580

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) ** in both National Classification and IPC IPC (4) C12N 7/100; G01N 33/53, 33/554, 33/569. U.S. C1 435/5, 7; 436/501, 518; 424/1.1, 3; 536/26-28		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched 7		
Classification System	Classification Symbols	
US	435/5, 7, 810; 436/501, 518, 519, 800, 808; 937/77, 78; 536/26-28; 424/1.1, 3.	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched 8		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT 9</b>		
Category *	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No. 13
Y	The EMBO Journal, volume 5 No. 8 issued 1986 August (Oxford, England), C. Ruppert et.al., "Proto-oncogene c-myc is Expressed in Cerebellar Neurons at Different Developmental Stages", pages 1897-1901, see the Abstract.	20
Y	L.H. Tecott, et. al. "Methodological Considerations in the Utilization of In Situ Hybridization" in "In Situ Hybridization: Applications to Neurobiology", published 1987, by Oxford University, pages 3-24, see pages 5, 9-10, 15, and 18.	1-31
<p>* Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
20 November 1989.		08 DEC 1989
International Searching Authority		Signature of Authorized Officer
ISA/US		Jack Spiege

Form PCT/ISA/210 (second sheet) (Rev. 11-87)

CGK00010496